Scientists test 'Vaccine' to train immune system to fight ovarian cancer
NCT ID NCT03029403
Summary
This study is testing whether a three-drug combination can help the body's immune system fight advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after initial treatment. The treatment includes an immunotherapy drug (pembrolizumab), an investigational cancer vaccine (DPX-Survivac), and a low-dose chemotherapy pill (cyclophosphamide). The goal is to see if this combination can shrink tumors and control the disease in 47 patients who have already had standard platinum-based chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.